183 related articles for article (PubMed ID: 35014061)
1. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
[TBL] [Abstract][Full Text] [Related]
2. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
Thomas D; Kanefendt F; Schwers S; Unger S; Yassen A; Boxnick S
J Thromb Haemost; 2021 Oct; 19(10):2407-2416. PubMed ID: 34192419
[TBL] [Abstract][Full Text] [Related]
3. First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
Nowotny B; Thomas D; Schwers S; Wiegmann S; Prange W; Yassen A; Boxnick S
J Thromb Haemost; 2022 Jul; 20(7):1684-1695. PubMed ID: 35490404
[TBL] [Abstract][Full Text] [Related]
4. The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.
Xu J; Zhao N; Huang J; Li J; Zhao X; Xiang Q; Yang S; Dong Y; Wang H; Li Y; Yang G; Cui Y
Clin Drug Investig; 2023 Jun; 43(6):435-445. PubMed ID: 37326942
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
6. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
9. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
11. ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study.
Beale D; Dennison J; Boyce M; Mazzo F; Honda N; Smith P; Bruce M
Br J Clin Pharmacol; 2021 Aug; 87(8):3177-3189. PubMed ID: 33450079
[TBL] [Abstract][Full Text] [Related]
12. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects.
Zenklusen I; Dingemanse J; Reh C; Gehin M; Kaufmann P
Drugs R D; 2024 Mar; 24(1):97-108. PubMed ID: 38472696
[TBL] [Abstract][Full Text] [Related]
13. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam.
Dingemanse J; Nicolas L; Binkert C
Fundam Clin Pharmacol; 2013 Dec; 27(6):698-710. PubMed ID: 22849770
[TBL] [Abstract][Full Text] [Related]
17. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults.
Berg AK; Myrvik MJ; Van Ess PJ
Epilepsy Behav; 2017 Jun; 71(Pt A):51-59. PubMed ID: 28544992
[TBL] [Abstract][Full Text] [Related]
20. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.
Wong SL; Goldberg MR; Ballow CH; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Feb; 30(2):136-43. PubMed ID: 20099988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
